The global range of patients allows and provides insights into the differences in disease management across the globe.
Key Data:
- Non-vitamin K antagonist oral anticoagulant (NOAC) uptake worldwide varies greatly
- 20,000 patients from cohorts 1-3 across Europe showed variations in NOAC uptake ranging from 2.6% to 58.0%
- Marked differences in AF management were observed in Asia compared with other regions of the world
- On average, patients in Asia treated with VKA:
- Were younger (67.1 years) than those in other regions of the world (71.3 years)
- Had lower CHA2DS2-VASc scores (3.0 versus 3.5) but similar HAS-BLED scores (1.3 versus 1.4)
- Mean international normalised ratio (INR) was lower in patients from other regions of the world (2.0) compared with those in Asia (2.4)
- The proportion of time in the therapeutic range (defined as INR 2.0-3.0) was substantially lower in Asia (33.1%) compared with other regions of the world (54.1%)
- 59.3% of INRs in Asia were <2, compared with 28.2% in other regions of the world
- 9.6% of INRs in Asia were >3, compared with 17.7% in other regions of the world
- On average, patients in Asia treated with VKA:
- Use of anticoagulants in Asian patients with a CHA2DS2-VASc score of ≥2 was lower
- Patients in Asia had a similar incidence of embolic stroke and lower incidences of major bleeding and all-cause mortality, compared with patients in other regions of the world